Global Pipeline Guide for Haemophilus influenzae type B infections 2021 and drugs in development

0

DUBLIN, August 19, 2021 / PRNewswire / – The report “Haemophilus influenzae Type B Infections (Infectious Disease) – Drugs In Development, 2021” has been added to ResearchAndMarkets.com offer.

The pipeline guide provides comprehensive information on treatments under development for Haemophilus influenzae type B infections (infectious disease), as well as analysis by stage of development, drug target, mechanism of action (MoA). , route of administration (RoA) and type of molecule. The guide covers the descriptive pharmacological action of therapy, its complete research and development history, and the latest news and press releases.

The guide also reviews the main players involved in the therapeutic development of Haemophilus influenzae type B infections and presents dormant and abandoned projects. The guide covers therapeutics under development by companies / universities / institutes, molecules developed by companies in pre-registration, phase III, phase I, IND / CTA filed, preclinical, discovery and unknown stages are 3, 5, 9, 1, 9, 2 and 2 respectively. Likewise, the portfolio of universities in phase III, preclinical and discovery comprises 1, 1 and 1 molecules respectively.

The guide helps identify and track emerging market players and their portfolios, enhance decision-making capabilities, and help create effective counter-strategies to gain competitive advantage. The guide is built using data and information from the publisher’s proprietary databases, company / university websites, clinical trial registers, conferences, SEC files, presentations to investors and press releases from company / university websites and industry-specific third-party sources. In addition, various dynamic tracking processes ensure that the most recent developments are captured in real time.

Scope of the report:

  • The pipeline guide provides an overview of the global therapeutic landscape for Haemophilus influenzae type B infections.
  • Pipeline Guide reviews pipeline therapeutics for Haemophilus influenzae type B infections by companies and universities / research institutes based on information from company and industry specific sources .
  • The Pipeline Guide covers the products in the pipeline based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide presents descriptive drug profiles for the products in the pipeline that include a product description, descriptive licensing and collaboration details, an R&D brief, an MoA, and other development activities.
  • The pipeline guide reviews the main companies involved in the therapy of Haemophilus influenzae type B infections and lists all their major and minor projects.
  • The pipeline guide assesses treatments for Haemophilus influenzae type B infections based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide summarizes all dormant and abandoned pipeline projects.
  • Pipeline guide reviews the latest news related to pipeline treatments for Haemophilus influenzae type B infections (infectious diseases)

Main topics covered:

Haemophilus influenzae type B infections – Overview

Pipeline overview

  • Pipeline by companies
  • Pipeline by universities / institutes
  • Products in development by companies
  • Products under development by universities / institutes

Haemophilus influenzae type B infections – Therapeutic evaluation

  • Evaluation by target
  • Assessment by mechanism of action
  • Assessment by administration
  • Evaluation by molecule type

Haemophilus influenzae type B infections – Companies involved in therapeutic development

  • AIM Vaccine Co Ltd
  • AVM Biotechnology LLC
  • Beijing Minhai Biotechnology Co Ltd
  • Biken Co Ltd
  • Organic E Ltd
  • Cadila Health Ltd.
  • CanSino Organic Products Inc
  • Changchun Heber Biotechnology Co Ltd
  • Chongqing Zhifei Organic Products Co Ltd
  • GlaxoSmithKline Plc
  • Hilleman Laboratories Pvt Ltd
  • KM Biologics Co Ltd
  • Liaoning Cheng Da Biotechnology Co Ltd
  • Novo Medi Sciences Pvt Ltd
  • Olymvax Biopharmaceuticals Inc
  • Orlance Inc
  • Panacea Biotec Ltée
  • Serum Institute of India Pvt Ltd
  • Shantha Biotechnics Pvt Ltd
  • Suzhou Weichao Biotechnology Co Ltd
  • Tuck-More Biotechnology Co Ltd
  • Vaxxilon SA
  • Wellstat Vaccines LLC
  • Yisheng Biopharma Co Ltd

Haemophilus influenzae type B infections – Drug profiles

  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B vaccine + pertussis (acellular, adsorbed) + rotavirus + tetanus) – Drug Profile
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B vaccine + pertussis + tetanus) (pentavalent) – Drug Profile
  • (diphtheria + haemophilus influenza [serotype B] + meningococcal vaccine + pertussis (acellular) + tetanus) – Drug Profile
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis vaccine (acellular) + polio + tetanus) – Drug Profile
  • (diphtheria + haemophilus influenza [serotype B] + pertussis vaccine (acellular) + polio + tetanus) – Drug Profile
  • (diphtheria + Haemophilus influenza [serotype B] Vaccine + pertussis (acellular) + tetanus) (tetravalent) – Drug Profile
  • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcus [serotype C] + pertussis vaccine (whole cell) + polio + tetanus) (heptavalent) – Drug profile
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B vaccine + pertussis (whole cell) + polio + tetanus) (hexavalent) – Drug Profile
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B vaccine + pertussis (whole cell) + polio + tetanus) (hexavalent) – Drug Profile
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B vaccine + pertussis (whole cell) + tetanus) (pentavalent) – Drug profile
  • (diphtheria + Haemophilus influenzae [serotype B] + pertussis vaccine (acellular) + tetanus) – Drug Profile
  • (diphtheria + Haemophilus influenzae [serotype B] + pertussis vaccine (whole cell) + polio + tetanus) (pentavalent) – Drug profile
  • (diphtheria + haemophilus influenzae [serotype B] + pertussis vaccine (whole cell) + tetanus) – Drug Profile
  • (diphtheria + tetanus + whooping cough (acellular) + haemophilus influenzae [serotype B]) vaccine – Drug profile
  • (diphtheria + tetanus + whooping cough + polio + haemophilus influenzae [serotype B]) vaccine – Drug profile
  • (Haemophilus influenzae [serotype B] + meningococcus [serotypes A, C]) vaccine – Drug profile
  • (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine – Drug profile
  • (meningococcal [4-valent] + hemophilus influenzae [serotype B]) vaccine – Drug profile
  • BK-1310 – Drug Profile
  • Dexamethasone Sodium Phosphate – Drug Profile
  • Haemophilus influenza B Vaccine – Drug Profile
  • Haemophilus influenzae [serotype B] vaccine – Drug profile
  • Haemophilus influenzae B Vaccine – Drug Profile
  • Influenza Vaccine – Drug Profile
  • KD-370 – Drug Profile
  • LT-Hib – Drug Profile

Haemophilus influenzae type B infections – Dormant projects

Haemophilus influenzae type B infections – Discontinued products

Haemophilus influenzae type B infections – Milestones in product development

Featured News & Press Releases

For more information on this report, visit https://www.researchandmarkets.com/r/okya5b

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for market research reports and international market data. We provide you with the latest data on international and regional markets, key industries, major companies, new products and the latest trends.

Media contact:
Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com

Leave A Reply

Your email address will not be published.